Immunoglobulin-related amyloidosis (AL amyloidosis)

“AL” means amyloid light chain. The light chains are produced by an abnormal plasma-cell clone, or less often a B-cell clone, and can form amyloid deposits in tissues. The clone may be small even when organ damage is serious.

AL is one type of amyloidosis. Accurate typing of the amyloid is essential because hereditary and other non-AL forms require different treatment. Finding a monoclonal protein alone does not prove that amyloid deposits are AL.

The disease involves an acquired antibody-producing clone and light chains with a tendency to misfold. The reason it develops in an individual is usually unknown.

AL amyloidosis itself is not the usual inherited form of amyloidosis and is not contagious. However, distinguishing it from other amyloid types requires tissue and laboratory assessment rather than assuming that every amyloid diagnosis has the same cause.

Deposits and light-chain toxicity can affect the heart, kidneys, nerves, liver, gut and soft tissues. Symptoms may include breathlessness, swelling, fatigue, dizziness on standing, numbness or digestive problems.

Heart involvement is especially important in assessing risk and treatment tolerance. Kidney protein loss and other organ effects may also need treatment. The amount of abnormal marrow plasma cells does not reliably describe the severity of organ disease.

Treatment targets the light-chain-producing clone, often with daratumumab and a bortezomib-based combination. The intensity must be adjusted to organ involvement and medical condition, especially severe cardiac disease.

Selected patients can receive high-dose melphalan with autologous stem cell rescue. Eligibility is stricter than for many other blood disorders because fragile heart, blood-pressure or organ function can make high-dose treatment dangerous. Response to initial drug therapy also affects whether and when transplantation is useful.

Supportive treatment for affected organs is essential. A fall in abnormal light chains is a hematologic response; organ improvement may take longer and may be incomplete. Stem cell rescue does not directly remove all existing amyloid deposits.

Care often involves several specialties. Fluid balance, blood pressure, kidney function, nutrition and nerve symptoms may need attention alongside the blood disorder. Ordinary advice for an otherwise healthy person may not fit someone with cardiac amyloidosis.

People may feel better at a different pace than their laboratory results improve. Transplant assessment should explain why a person is or is not eligible and how drug treatment and organ support will continue if transplant is unsuitable.

The usual stem cell transplant used for AL amyloidosis is autologous and uses the patient’s own cells. It supports recovery after chemotherapy directed at the abnormal clone.

An unrelated registry donor is not part of this usual pathway, and allogeneic transplantation is not routine AL treatment. Donor recruitment supports the wider population of patients who need donated stem cells; it should not imply that most people with AL amyloidosis are waiting for a donor.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?